Navigation Links
Dr. Gail Naughton Speaks on Histogen's Business Plan and the Rise of Bioaesthetic Medicine during Commercial Translation of Regenerative Medicine
Date:11/17/2008

s grown in a simulated embryonic environment, is currently being evaluated for a variety of applications, from dermal fillers to implant coatings," said Dr. Robert Kellar, VP of Research and Development at Histogen. "Intriguing preliminary results from ongoing ExCeltrix research shows promise of in the field of oncology."

Dr. Naughton presented data for the first time supporting the ability of ExCeltrix to diminish or eliminate tumor load in preclinical trials. Studies were performed with three rapidly growing human tumor cell lines: melanoma, adenocarcinoma, and glioma. Cancer cells were either mixed with ExCeltrix or delivered alone in two preclinical models. In the CAM model (chollioallantoic membrane) tumor mass was significantly reduced by the presence of ExCeltrix. In the nude mouse model, cells with ExCeltrix showed little to no tumor growth, in comparison to the control which did form palpable tumors.

Dr. Gail Naughton has spent more than 15 years extensively researching the tissue engineering process, and holds more than 90 patents in the field. Dr. Naughton founded Histogen in 2007, and currently serves as Chief Executive Officer and Chairman of the Board for the Company, in addition to her position as Dean of the College of Business at San Diego State University.

About Histogen
Histogen, launched in 2007, seeks to redefine regenerative medicine by developing a series of high value products that do not contain embryonic stem cells or animal components. Through Histogen's proprietary bioreactors that mimic the embryonic environment, newborn fibroblasts are encouraged to naturally produce the vital proteins and growth factors from which the company has developed its rich product portfolio. Histogen has two product families - ExceltrixTM, Histogen's human Extracellular Matrix (ECM) and ReGenicaTM, Histogen's proprietary liquid formula. For more information, please visit '/>"/>

Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Frost & Sullivan Awards Baxters BioPharma Solutions Business the 2008 North American Customer Service Leadership of the Year Award
2. Confirmation of HGT Business Day - 18th November 2008
3. PointCross Releases Catalyst for Building Business-Ready SharePoint Solutions in 1/10th the Time
4. Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units
5. South Africas Minister of Minerals and Energy Welcomes Denham Capital Investment in BioTherm Energy to Develop Power Generation Business
6. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
7. ADVENTRX Pharmaceuticals Reports Third Quarter 2008 Financial Results and Business Update
8. ThromboGenics N.V.: Business Update
9. Genomic Health Announces Third Quarter 2008 Financial Results and Business Progress
10. Kendle Reports Record 3Q 08 Net Income and Total Business Authorizations
11. Amgen to Webcast 2008 Business Review Meeting on November 7 From Millennium Hotel in New York
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... (PRWEB) October 30, 2014 The report ... Chemicals), by Application (Cosmetics & Toiletries, and Soaps & ... to 2019”, has defined and segmented the Fragrance Ingredients ... trends in terms of value. The market has been ... North America, Europe, Asia-Pacific, Latin America, and Rest of ...
(Date:10/30/2014)... 2014 Deep Research Report on Global ... and in-depth research report on the China Naltrexone ... including its definition, classification, application, and industry chain ... covers the international market analysis, including China’s domestic ... macroeconomic environment & economic situation analysis. The report ...
(Date:10/30/2014)... James Sherley says he has been working ... cell technology since his days as a principal investigator at ... late 1990’s. Sherley founded the ASCTC as a new ... the intellectual property developed in Sherley’s research over the years ... of Technology (MIT), and more recently as a senior scientist ...
(Date:10/30/2014)... October 30, 2014 Grace Century portfolio project, ... A. Manganello, Chairman of the Board, to the National ... The appointment was made by the Ministry of Health on ... 2014. , More than a year after Bahamian ... , Prime Minister Perry Christie said the government has completed ...
Breaking Biology Technology:Fragrance Ingredients Market worth $17,104.21 Million by 2019 - New Report by MarketsandMarkets 2Fragrance Ingredients Market worth $17,104.21 Million by 2019 - New Report by MarketsandMarkets 3Fragrance Ingredients Market worth $17,104.21 Million by 2019 - New Report by MarketsandMarkets 4Fragrance Ingredients Market worth $17,104.21 Million by 2019 - New Report by MarketsandMarkets 5Naltrexone HCL Market & Nalbuphine HCL Industry Analysis for Global, China Regions Now at DeepResearchReports.com 2Naltrexone HCL Market & Nalbuphine HCL Industry Analysis for Global, China Regions Now at DeepResearchReports.com 3Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 2Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 3Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 4Grace Century’s Stem Cell Biobank Project Announces Chairman’s Appointment to National Stem Cell Ethics Committee of The Bahamas 2Grace Century’s Stem Cell Biobank Project Announces Chairman’s Appointment to National Stem Cell Ethics Committee of The Bahamas 3
... PHILADELPHIA, Aug. 23, 2011 FMC Corporation (NYSE: ... has entered into two exclusive agreements covering global development ... and ornamental markets.  FMC will begin commercialization this year ... start development for new biological standalone and combination products ...
... Additional   Funds to   Broaden   ... , AU$6.25M (US$6.5M) investment by GBS Venture Partners, ... additional Phase 2 studies will run in parallel with planned clinical ... an Australian pain drug development company, today announced it has ...
... not easy, especially for tiny nanowires: With no ... difficult to harness their full potential as effective ... Chemistry Faculty has found a way to grow ... providing, for the first time, the much-needed guidance ...
Cached Biology Technology:FMC Corporation Announces Exclusive Global Development and Supply Agreements for Chr. Hansen Biological Products 2Spinifex Closes AU$18.25M(~US$19M) Expanded Series B Round 2Spinifex Closes AU$18.25M(~US$19M) Expanded Series B Round 3Spinifex Closes AU$18.25M(~US$19M) Expanded Series B Round 4Spinifex Closes AU$18.25M(~US$19M) Expanded Series B Round 5Nanowires get into the groove 2
(Date:10/29/2014)... consequence of chemotherapy will benefit from a major research ... prevents hair loss. , The research is being now ... manufacturing company, Paxman Coolers, of Fenay Bridge, Huddersfield, in ... Huddersfield. , The research will be led by key ... pharmacology of cancer treatment, which he will use towards ...
(Date:10/29/2014)... but they also need protection from its harmful rays, just ... in plants that shields them from sun damage. Now, in ... Society , one team reports on the mechanics of how ... at Purdue University note that the harsh ultraviolet radiation plants ... DNA and, as a result, hinder plant growth. Biochemical ...
(Date:10/29/2014)... German . ... Peter Schlögelhofer at the Max F. Perutz Laboratories (MFPL) ... of Vienna dived into the process of meiosis in ... an inversion of the standard meiotic phases. The researchers ... Nature Communications . , Meiosis is the two-step series ...
Breaking Biology News(10 mins):New technology on the way to aid cancer suffers who lose their hair after chemotherapy 2Meiotic cell division 'the other way round' 2
... as a series of random changes, might in fact be ... environmental pressure that a broad range of specieshappen to share, ... the journal Science suggests that knowledge of a ... proteins encoded by those genes could be used to ...
... JoVE , Journal of Visualized Experiments , details ... chitosan-based polymer, SurgiLux, was developed by scientists at the ... derived from chitin, which is found in fungal cell ... component allows SurgiLux to form low energy bonds between ...
... MANHASSET, NY The Feinstein Institute for Medical Research ... World Trade Center Health Program, which is administered by ... part of the US Centers for Disease Control and ... Health and Safety (NIOSH) to comprehensively study the overall ...
Cached Biology News:Far from random, evolution follows a predictable genetic pattern, Princeton researchers find 2Far from random, evolution follows a predictable genetic pattern, Princeton researchers find 3Far from random, evolution follows a predictable genetic pattern, Princeton researchers find 4Far from random, evolution follows a predictable genetic pattern, Princeton researchers find 5New bio-adhesive polymer demonstrated in JoVE 2Feinstein Institute receives $1 million grant to study impact of World Trade Center attacks on responders 2
Rabbit polyclonal antibody to GluR2...
... Blocker Array II can be used ... against various proteins and sera that are ... carriers. The array contains spots for 19 ... Application: Determination of antibody crossreactivity and species ...
... Each kit contains sufficient materials for 1,464 array ... Membrane: 4 each , Blocker BSA ... Goat Anti-Mouse Antibody, HRP-conjugated: 10 g ... , 10% Tween-20: 2 x 10 ml ...
... gun system, 100-120 V, is used for ... This handheld device employs an adjustable helium ... biomaterial-coated gold microcarriers from the inner wall ... target cells. This system has a 2 ...
Biology Products: